The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Series A | Alive

Total Raised


Last Raised

$72M | 1 yr ago

About Aktis Oncology

Aktis Oncology is a biotechnology company that discovers and develops a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.

Aktis Oncology Headquarter Location

Cambridge, Massachusetts,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aktis Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aktis Oncology is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Aktis Oncology News

08:00 ET Aktis Oncology Expands Leadership Team with Two Strategic Hires

Jan 18, 2022

News provided by Share this article Share this article CAMBRIDGE, Mass., Jan. 18, 2022 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers, today announced the expansion of their leadership team and scientific capabilities through the appointments of Tyler Benedum, PhD, as Senior Vice President, Head of Chemistry, Manufacturing, and Controls (CMC), and Daša Lipovšek, PhD, as Vice President, Head of Lead Discovery. "I am excited to welcome Tyler and Daša to the Aktis Oncology team, as I believe their expertise across key aspects of research and development will prove to be invaluable assets to our capabilities and growth of our pipeline," said Matthew Roden, PhD, President, and Chief Executive Officer of Aktis Oncology. "These additions to our leadership team will help us further develop our programs as we work towards realizing the curative power of alpha radiopharmaceuticals for mainstream cancer care." Dr. Benedum's role at Aktis will focus on developing radiopharmaceuticals, establishing a manufacturing network, and oversight of CMC regulatory. He spent over sixteen years at Avid Radiopharmaceuticals which, during his tenure, became a wholly owned subsidiary of Eli Lilly and Company. He joined Avid in its infancy as a Research Chemist and consistently held increasing levels of responsibility from Director of Manufacturing Operations to Senior Director of Chemical Development and Manufacturing, and most recently, Vice President of CMC Development and Manufacturing. During his time at Avid, Dr. Benedum played a key role in developing and advancing AMYVID and TAUVID (both Alzheimer's Disease positron emission tomography (PET) diagnostic imaging agents) through marketing authorization approval and commercialization. Further, he built a global manufacturing network to supply Alzheimer's Disease clinical trials. He received a B.S. in Chemistry from Washington College and a PhD in Organic Chemistry from the University of Virginia. He then completed his Postdoctoral Fellowship in natural product synthesis at the University of Pittsburgh. Dr. Lipovšek joins Aktis with a background in engineering target-binding proteins for therapeutic and diagnostic applications. At Aktis, she will further expand and develop the company's pipeline of radiopharmaceuticals. Most recently, she served at Bristol Myers Squibb as Scientific Associate Director, Selection Technologies and Protein Engineering, where her group was responsible for the development of library-based protein-engineering methods and for their application to drug discovery. She also served as Director, Protein Design, for Adnexus Therapeutics, a Bristol Myers Squibb R&D Company. Prior to her time at Bristol Myers Squibb, Dr. Lipovšek's roles include Director of Protein Engineering at Codon Devices, Inc., Visiting Scientist in Biological Engineering at MIT, and Associate Director of Biochemistry at Phylos, Inc. Dr. Lipovšek received a B.S. in Biology from MIT and a PhD in Chemistry from the University of Cambridge. About Aktis Oncology Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. To learn more about Aktis Oncology, visit . SOURCE Aktis Oncology

Aktis Oncology Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aktis Oncology Rank

  • Where is Aktis Oncology's headquarters?

    Aktis Oncology's headquarters is located at Cambridge.

  • What is Aktis Oncology's latest funding round?

    Aktis Oncology's latest funding round is Series A.

  • How much did Aktis Oncology raise?

    Aktis Oncology raised a total of $72M.

  • Who are the investors of Aktis Oncology?

    Investors of Aktis Oncology include MPM Capital, Bristol-Myers Squibb, Novartis, EcoR1 Capital, Vida Ventures and 4 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.